Meeting
2024 ASCO Gastrointestinal Cancers Symposium
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
Authors
Kevin Kim
University of Maryland School of Medicine, Baltimore, MD
Kevin Kim , Anwaar Saeed , Davendra Sohal , Julien Edeline , Jeong Heo , Aditya Bhansali , Shaheen Kumar , Guy Ungerechts
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05733598
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS576)
DOI
10.1200/JCO.2024.42.3_suppl.TPS576
Abstract #
TPS576
Poster Bd #
P5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
First Author: Tanios S. Bekaii-Saab
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
First Author: Tanios S. Bekaii-Saab
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
First Author: Daneng Li
Poster
2023 ASCO Annual Meeting
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
First Author: Dale Randall Shepard